# Enforcement Policy on Marketing OTC Combination Products (CPG 7132b16) - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-on-marketing-otc-combination-products-cpg-7132b16/2c77f827-6c1a-4709-983c-c8314f614c3b

> FDA guidance document: Enforcement Policy on Marketing OTC Combination Products (CPG 7132b16). Issue date: May 01, 1984. Get complete insights and analysis.

---

## Details

- Title: Enforcement Policy on Marketing OTC Combination Products (CPG 7132b16)
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 1984-05-01
- Last Changed: 2019-04-10

## Related Documents

- [Guidance for the Development of Vaginal Contraceptive Drugs (NDA)](https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-development-of-vaginal-contraceptive-drugs-nda/274b67c2-e9a6-4c70-a492-00f91e8df6dd)
- [Preparation of Investigational New Drug Products (Human and Animal):  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/preparation-of-investigational-new-drug-products-human-and-animal-guidance-for-industry/4382914f-5b98-4ad4-91c1-ed6e2893e213)
- [Topical Dermatologic Corticosteroids: in Vivo Bioequivalence](https://www.globalkeysolutions.net/guidances/guidance-document/topical-dermatologic-corticosteroids-in-vivo-bioequivalence/7ffc2692-ebeb-401d-92f6-3b735fadd8d6)